You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康希諾生物(06185.HK)公佈中期業績 研發開支增加87.6% 將盡快推動新冠疫苗國際多中心III期臨牀試驗
格隆匯 08-21 22:42

格隆匯8月21日丨康希諾生物(06185.HK)公告,截至2020年6月30日止6個月,公司尚未將任何產品商業化,因此並未取得任何收入。期間虧損1.02億元人民幣,虧損同比擴大46.7%;每股虧損0.46元。

公司的研發開支由截至2019年6月30日止6個月的人民幣5750萬元增加87.6%至截至2020年6月30日止6個月的人民幣1.08億元,主要由於在報告期間開發的在研疫苗。

公司的疫苗產品線在戰略上旨在針對中國龐大且供不應求的市場,可總結為三個類別:(i)全球創新疫苗(如Ad5-EBOV、公司的在研結核病加強疫苗、在研PBPV及在研Ad5-nCoV),以迎合世界尚未滿足的醫療需求;(ii)研發潛在的中國首創疫苗,憑藉質量更高的世界級疫苗取代現時的主流疫苗(如公司的在研DTcP疫苗及在研MCV4);及(iii)研發出與中國市場的進口產品競爭的中國潛在最佳疫苗(如公司的在研PCV13i)。

公司正為13個疾病領域研發16種在研疫苗。除了公司預防腦膜炎球菌感染及埃博拉病毒疫病的三項臨近商業化疫苗產品之外,公司有七種在研疫苗處於臨牀試驗階段或臨牀試驗申請階段。公司亦有六種臨牀前在研疫苗,包括一種在研聯合疫苗。迄今為止,公司尚未將任何產品商業化,公司亦無法保證公司將能夠成功研發及商業化公司的在研疫苗。

此外,於2020年8月11日,公司收到授予“一種以人複製缺陷腺病毒為載體的重組新型冠狀病毒疫苗”的發明專利權通知書。該專利由中國人民解放軍軍事科學院軍事醫學研究院與公司聯合申請。公司目前正在與多個國家聯繫,計劃儘快推動Ad5-nCoV國際多中心III期臨牀試驗。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account